keyword
MENU ▼
Read by QxMD icon Read
search

New treatment in HCV

keyword
https://www.readbyqxmd.com/read/29165831/external-validation-of-the-ita-li-ca-prognostic-system-for-patients-with-hepatocellular-carcinoma-a-multicenter-cohort-study-hep-17-0903
#1
Mauro Borzio, Elena Dionigi, Angelo Rossini, Massimo Marignani, Rodolfo Sacco, Ilario De Sio, Emanuela Bertolini, Giampiero Francica, Anna Giacomin, Giancarlo Parisi, Susanna Vicari, Anna Toldi, Andrea Salmi, Sergio Boccia, Mario Mitra, Fabio Fornari
Several staging systems for HCC have been developed. BCLC is considered the best in predicting survival, although limitations have emerged. Recently the Italian-Liver-Cancer (ITA.LI.CA) prognostic system, integrating the ITA.LI.CA tumor-staging (stages 0, A, B1-3; C) with Child-Pugh score, ECOG-PST, and AFP with a strong ability to predict survival was proposed. Aim of our study was to provide an external validation of the ITA.LI.CA system in an independent real-life occidental cohort of HCCs. METHODS: From September 2008 to April 2016, 1508 cirrhotics with incident HCC were consecutively enrolled in 27 Italian institutions (EpaHCC multi-institutional cohort)...
November 22, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29158855/clinical-evaluation-of-terap-c-vaccine-in-combined-treatment-with-interferon-and-ribavirin-in-patients-with-hepatitis-c
#2
Dorta Guridi Zaily, Castellanos Fernandez Marlen, Dueñas-Carrera Santiago, Martínez Donato Gillian, Valenzuela Silva Carmen, Cinza Estevez Zurina, Arús Soler Enrique R, Alvarez-Lajonchere Liz, González Fabián Lisset, Lazo Del Vallín Sacha, Ferrer Bataille Elena
Background: An estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). Although treatment options using a combination of pegylated interferon and ribavirin (P-IFN/RBV) are available, sustained clearance of the virus is only achieved in approximately 40% of individuals infected with HCV genotype 1. Recent advances in the treatment of HCV using directly acting antiviral agents have been achieved; however, treatment can be very expensive and is associated with substantial side effects...
2017: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/29153265/hepatitis-c-virus-treatment-as-prevention-in-an-extended-network-of-people-who-inject-drugs-in-the-usa-a-modelling-study
#3
Alexei Zelenev, Jianghong Li, Alyona Mazhnaya, Sanjay Basu, Frederick L Altice
BACKGROUND: Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in the USA and concentrated in people who inject drugs. Treatment as prevention with highly effective new direct-acting antivirals is a prospective HCV elimination strategy. We used network-based modelling to analyse the effect of this strategy in HCV-infected people who inject drugs in a US city. METHODS: Five graph models were fit using data from 1574 people who inject drugs in Hartford, CT, USA...
November 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29143676/the-future-of-viral-hepatitis-testing-innovations-in-testing-technologies-and-approaches
#4
REVIEW
Rosanna W Peeling, Debrah I Boeras, Francesco Marinucci, Philippa Easterbrook
A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most people with hepatitis remain unaware of their infection. Advances in rapid detection technology have created new opportunities for enhancing access to testing and care, as well as monitoring of treatment. This article examines a range of other technological innovations that can be leveraged to provide more affordable and simplified approaches to testing for HBV and HCV infection and monitoring of treatment response...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29136329/follow-up-of-sustained-virologic-responders-with-hepatitis-c-and-advanced-liver-disease-after-interferon-ribavirin-free-treatment
#5
Karin Kozbial, Stephan Moser, Ramona Al-Zoairy, Remy Schwarzer, Christian Datz, Rudolf Stauber, Hermann Laferl, Michael Strasser, Sandra Beinhardt, Albert Friedrich Stättermayer, Michael Gschwantler, Heinz Zoller, Andreas Maieron, Ivo Graziadei, Michael Trauner, Petra Steindl-Munda, Harald Hofer, Peter Ferenci
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty one patients with advanced fibrosis (n=158) or liver cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65...
November 14, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29135373/high-dose-of-silymarin-in-patients-with-decompensated-liver-disease-a-randomized-controlled-trial
#6
Waleed Fouad Fathalah, Mohamed AbdAllah Abdel Aziz, Neveen Helmy Abou El Soud, Maissa El Said El Raziky
Hepatitis C virus (HCV) is a major public health problem being the most common cause of chronic liver disease in Egypt. HCV-induced decompensated liver cirrhosis patients have a median survival of 2 years even with currently used new treatments. Silymarin is the most commonly used herbal product in chronic liver disease for its anti-inflammatory, antiviral, antioxidant, and antifibrotic effects. The aim of this study was to assess the effects of silymarin in high dose on the clinical and biochemical status of chronic HCV-associated decompensated liver cirrhosis...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29121533/novel-treatments-for-chronic-hepatitis-c-closing-the-remaining-gaps
#7
REVIEW
Naim Alkhouri, Eric Lawitz, Fred Poordad
Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review...
November 6, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29120012/hepatitis-c-virus-dynamics-among-intravenous-drug-users-suggest-that-an-annual-treatment-uptake-above-10-would-eliminate-the-disease-by-2030
#8
Philip Bruggmann, Sarah Blach, Pierre Deltenre, Jan Fehr, Roger Kouyos, Daniel Lavanchy, Beat Müllhaupt, Andri Rauch, Homie Razavi, Patrick Schmid, David Semela, Marcel Stoeckle, Franco Negro
BACKGROUND AND AIMS: In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and preventing new infections. In order to guide these efforts, the current project was undertaken with the following aims: (1) to develop a simple model to estimate the number of new HCV infections using available data on PWID; (2) to examine the impact of intervention strategies (prevention and treatment) on new and total HCV infections among PWID...
November 9, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29107152/the-contribution-of-alcohol-use-disorder-to-decompensated-cirrhosis-among-people-with-hepatitis-c-an-international-study
#9
Maryam Alavi, Naveed Z Janjua, Mei Chong, Jason Grebely, Esther J Aspinall, Hamish Innes, Heather M Valerio, Behzad Hajarizadeh, Peter C Hayes, Mel Krajden, Janaki Amin, Matthew G Law, Jacob George, David J Goldberg, Sharon J Hutchinson, Gregory J Dore
BACKGROUND: The aim of this study was to evaluate the contribution of alcohol-use disorder to hepatitis C virus (HCV)-related decompensated cirrhosis diagnosis in three settings. METHODS: HCV notifications from British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to hospital admissions (2001-2012/2013/2014, respectively). Alcohol-use disorder was defined by non-liver-related hospitalisation due to alcohol use...
October 26, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29105320/impact-of-hepatitis-c-virus-hcv-antiviral-treatment-on-the-need-for-liver-transplantation-lt
#10
Esteban Sáez-González, Carmen Vinaixa, Fernando San Juan, Vanesa Hontangas, Salvador Benlloch, Victoria Aguilera, Angel Rubín, María García, Martín Prieto, Rafa López-Andujar, Marina Berenguer
BACKGROUND: Therapies for hepatitis C virus (HCV) infection have revolutionized the treatment of patients with chronic HCV infection. The effect of these therapies on the epidemiology of liver transplantation (LT) has yet to be elucidated. AIM: To establish whether the indications for LT have changed as a result of the introduction of new therapies for HCV. MATERIALS AND METHODS: We conducted a retrospective study based on a prospectively maintained registry of patients who undergo LT at La Fe Hospital in Valencia from 1997 to 2016...
November 4, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29105286/strategies-to-manage-hepatitis-c-virus-infection-disease-burden-volume-4
#11
D S Chen, W Hamoudi, B Mustapha, J Layden, A Nersesov, T Reic, V Garcia, C Rios, L Mateva, O Njoya, S A Al-Busafi, M K Abdelmageed, M Abdulla, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, I Al Ghazzawi, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, J Fung, I Gamkrelidze, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, S M Himatt, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, K S Kaliaskarova, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A Maaroufi, A O Malu, R Mitova, R Mohamed, M Morović, K Murphy, H Nde, E Ngige, R Njouom, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, O Opare-Sem, S Owusu-Ofori, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, K Razavi-Shearer, B Redae, T Rinke de Wit, S Robbins, L R Roberts, S J Sanad, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, A Vince, H U Wani, V W S Wong, A Workneh, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, J D Schmelzer
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29102620/levels-of-cytokines-in-serum-associate-with-development-of-hepatocellular-carcinoma-in-patients-with-hcv-infection-treated-with-direct-acting-antivirals
#12
Jose D Debes, Marjolein van Tilborg, Zwier M A Groothuismink, Bettina E Hansen, Julian Schulze Zur Wiesch, Johann von Felden, Robert J de Knegt, Andre Boonstra
Concern has arisen about development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs). To identify patients at risk for HCC, we evaluated serum levels of immune mediators before, during, and after DAA treatment of HCV infection. Our study included 13 patients who developed HCC within 18 months after treatment (3 with HCC recurrence and 10 with new HCC) and 10 patients who did not develop HCC (controls), within at least 24 months of treatment (median, 26 months)...
November 1, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29098647/current-and-future-challenges-in-hcv-insights-from-an-italian-experts-panel
#13
REVIEW
Massimo Andreoni, Sergio Babudieri, Savino Bruno, Massimo Colombo, Anna L Zignego, Vito Di Marco, Giovanni Di Perri, Carlo F Perno, Massimo Puoti, Gloria Taliani, Erica Villa, Antonio Craxì
BACKGROUND: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. METHODS: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens...
November 2, 2017: Infection
https://www.readbyqxmd.com/read/29098140/mpgn-and-mixed-cryoglobulinemia-in-a-patient-with-hepatitis-c-new-treatment-implications-and-renal-outcomes
#14
Shannon B Palombo, Eric C Wendel, Laura R Kidd, Farshid Yazdi, Mihran V Naljayan
. INTRODUCTION: The association of hepatitis C virus (HCV), cryoglobulinemia, and membranoproliferative glomerulonephritis (MPGN) is well known. Treatment of underlying HCV infection has greatly improved in recent years with the introduction of direct-acting antivirals (DAA), which have demonstrated curative sustained viral response (SVR) rates for select viral genotypes with the added benefit of less drug side effects. However, a mainstay of newer DAAs is sofosbuvir, which is contraindicated in patients with severe renal impairment...
2017: Clin Nephrol Case Stud
https://www.readbyqxmd.com/read/29091196/efficacy-and-safety-of-direct-antiviral-agents-in-a-cohort-of-cirrhotic-hcv-hiv-coinfected-patients
#15
Jordi Navarro, Montserrat Laguno, Helem Haydee Vilchez, Jose M Guardiola, Jose A Carrion, Luis Force, Mireia Cairó, Carmen Cifuentes, Josep Vilaró, Josep Cucurull, Andrés Marco, Mercè Roget, Eva Erice, Manuel Crespo
Background: New direct-acting antiviral agents (DAAs) have shown great efficacy and tolerability in clinical trials and real-life cohorts. However, data are scarce regarding efficacy and safety in cirrhotic HCV/HIV-coinfected patients. Methods: A multicentre prospective analysis was performed in 13 Spanish hospitals, including all cirrhotic HCV/HIV-coinfected patients starting DAA combinations from January to December 2015. Sustained virological response 12 weeks after treatment (SVR12) was analysed...
October 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29089195/superior-immunogenicity-of-hcv-envelope-glycoproteins-when-adjuvanted-with-cyclic-di-amp-a-sting-activator-or-archaeosomes
#16
A Landi, J Law, D Hockman, M Logan, K Crawford, C Chen, J Kundu, T Ebensen, C A Guzman, L Deschatelets, L Krishnan, D L J Tyrrell, M Houghton
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver transplantation and poses a major threat to global health. In spite of recent advances in the development of direct acting antivirals, there is still a need for a prophylactic vaccine to limit the virus spread and protect at-risk populations, especially in developing countries, where the cost of the new treatments may severely limit access. The use of recombinant HCV glycoproteins E1E2 (rE1E2) in combination with the MF59, an oil-in-water emulsion-based adjuvant, has previously been shown to reduce the rate of chronicity in chimpanzees and to induce production of cross-neutralizing antibodies and cellular immune responses in human volunteers...
October 28, 2017: Vaccine
https://www.readbyqxmd.com/read/29080808/model-projections-on-the-impact-of-hcv-treatment-in-the-prevention-of-hcv-transmission-among-people-who-inject-drugs-in-europe
#17
Hannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, Patrizia Carrieri, Olav Dalgard, John Dillon, David Goldberg, Sharon Hutchinson, Marie Jauffret-Roustide, Martin Kåberg, Amy A Matser, Mojca Matičič, Havard Midgard, Viktor Mravcik, Anne Øvrehus, Maria Prins, Jens Reimer, Geert Robaeys, Bernd Schulte, Daniela K van Santen, Ruth Zimmermann, Peter Vickerman, Matthew Hickman
BACKGROUND: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical to eliminating HCV in Europe. We estimate impact of current and scaled-up HCV treatment with and without scaling-up opioid substitution therapy (OST) and needle and syringe programmes (NSP) across Europe over the next 10 years. METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST and NSP coverage from 11 European settings...
October 25, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29077766/peripheral-blood-hiv-1-dna-dynamics-in-antiretroviral-treated-hiv-hcv-co-infected-patients-receiving-directly-acting-antivirals
#18
Gabriella Rozera, Gabriele Fabbri, Patrizia Lorenzini, Ilaria Mastrorosa, Laura Timelli, Mauro Zaccarelli, Alessandra Amendola, Alessandra Vergori, Maria Maddalena Plazzi, Stefania Cicalini, Andrea Antinori, Maria Rosaria Capobianchi, Isabella Abbate, Adriana Ammassari
BACKGROUND: Aim was to determine the dynamics of peripheral blood mononuclear cells (PBMC)- associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the phenomenon. METHODS: Longitudinal, single-centre study measuring total HIV-1 DNA before the start of DAA, at the end of treatment (EOT), and 3 months after treatment. Univariable and multivariable analyses were used to assess factors associated with HIV-1 DNA increase ≥0...
2017: PloS One
https://www.readbyqxmd.com/read/29074450/cost-effectiveness-of-access-expansion-to-treatment-of-hepatitis-c-virus-infection-through-primary-care-providers
#19
Thilo Rattay, Ian P Dumont, Hauke S Heinzow, David W Hutton
BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major burden on individuals and health care systems. The Extension for Community Healthcare Outcomes (Project ECHO) enables primary care providers to deliver best-practice care for complex conditions to underserved populations. The US Congress passed the ECHO Act in late 2016, requiring the Department of Health and Human Services to investigate the model. We performed a cost-effectiveness analysis to assess diagnosis and treatment of HCV infection in a primary care patient panel with and without the implementation of Project ECHO...
October 23, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29073993/cost-effectiveness-analysis-of-new-hcv-treatments-in-egyptian-cirrhotic-and-non-cirrhotic-patients-a-societal-perspective
#20
Gihan Hamdy Elsisi, Asmaa Aburawash, Emam Waked
OBJECTIVES: To evaluate the cost-effectiveness of sofosbuvir (SOF) + ribavirin (RBV), SOF + daclatasvir (DCV), and SOF + ledipasvir (LDV) + RBV compared with SOF + pegylated interferon alfa (pegIFN) + RBV in the treatment of patients infected with hepatitis C virus in Egypt. METHODS: Two Markov models were developed on the basis of the Egyptian clinical data and practice and were derived from published sources. The clinical parameters were derived from two sources: the Egypt multicenter national treatment program and previously published randomized clinical trials...
September 2017: Value in Health Regional Issues
keyword
keyword
36135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"